The Frazier Life Sciences team invests in and builds companies developing and commercializing novel therapeutics.

500+

Collective years of investing and operational experience

100

Portfolio companies

60

M&A and IPOs

29

FDA approved drugs since 2010

Selected M&A and IPOs

Acquired by AstraZeneca in 2016
IPO in 2017 (NASDAQ: ANAB)
IPO in 2018; Acquired by Eli Lilly in 2018
IPO in 2018 (NASDAQ: GRTS)
IPO in 2014; Acquired by Roche in 2018
NASDAQ: IOVA
Acquired by AbbVie in 2019
Acquired by CutisPharma in 2019

Life Sciences News

Mavupharma

AbbVie Enhances Early Stage Oncology Pipeline with Acquisition of Mavupharma

Silvergate Pharmaceuticals

CutisPharma Announces Acquisition of Silvergate Pharmaceuticals, Name Change to Azurity Pharmaceuticals

Phathom Pharmaceuticals

Takeda and Frazier Healthcare Partners Announce Collaboration to Launch Phathom Pharmaceuticals

Passage Bio

Passage Bio Launches with $115.5 Million Series A to Develop AAV-Delivered Therapeutics to Treat Rare Monogenic CNS Diseases

View All News